Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J A Adams

Showing results (81-90 of 251) with videos related to

Pageof 26
Sort By:
Biochemistry|January 28, 1999
Mutations in the activation loop tyrosine of the oncoprotein v-FpsP Saylor, E Hanna, J A Adams
Annals of Hematology|September 4, 2016
End-of-treatment FDG-PET lacks usefulness in Hodgkin lymphomaHugo J A Adams, Thomas C Kwee
Critical Reviews in Oncology/Hematology|September 18, 2016
Prognostic value of interim FDG-PET in R-CHOP-treated diffuse large B-cell lymphoma: Systematic review and meta-analysisHugo J A Adams, Thomas C Kwee
Biochemistry|September 12, 2001
Nucleotide release and associated conformational changes regulate function in the COOH-terminal Src kinase, CskJ Shaffer, G Sun, J A Adams
British Journal of Haematology|September 15, 2017
Interim FDG-PET has no value in selecting patients who require treatment modification in both early- and advanced-stage Hodgkin lymphomaHugo J A Adams, Thomas C Kwee
British Journal of Haematology|June 29, 2016
Overestimated value of FDG-PET based bone marrow evaluation in lymphomaHugo J A Adams, Thomas C Kwee
European Journal of Nuclear Medicine and Molecular Imaging|July 15, 2017
Unproven value of end-of-treatment FDG-PET in Hodgkin lymphomaHugo J A Adams, Thomas C Kwee
European Journal of Radiology|October 26, 2016
Proportion of false-positive lesions at interim and end-of-treatment FDG-PET in lymphoma as determined by histology: Systematic review and meta-analysisHugo J A Adams, Thomas C Kwee
British Journal of Haematology|December 28, 2016
Hodgkin lymphoma: is there really a need for interim and end-of-treatment FDG-PET evaluations?Hugo J A Adams, Thomas C Kwee
British Journal of Haematology|November 16, 2018
Interim FDG-PET does not predict outcome in advanced-stage Hodgkin lymphoma patients treated with BEACOPPHugo J A Adams, Thomas C Kwee
Pageof 26

Showing results (81-90 of 251) with videos related to

Sort By:
Pageof 26
Biochemistry|January 28, 1999
Mutations in the activation loop tyrosine of the oncoprotein v-FpsP Saylor, E Hanna, J A Adams
Annals of Hematology|September 4, 2016
End-of-treatment FDG-PET lacks usefulness in Hodgkin lymphomaHugo J A Adams, Thomas C Kwee
Critical Reviews in Oncology/Hematology|September 18, 2016
Prognostic value of interim FDG-PET in R-CHOP-treated diffuse large B-cell lymphoma: Systematic review and meta-analysisHugo J A Adams, Thomas C Kwee
Biochemistry|September 12, 2001
Nucleotide release and associated conformational changes regulate function in the COOH-terminal Src kinase, CskJ Shaffer, G Sun, J A Adams
British Journal of Haematology|September 15, 2017
Interim FDG-PET has no value in selecting patients who require treatment modification in both early- and advanced-stage Hodgkin lymphomaHugo J A Adams, Thomas C Kwee
British Journal of Haematology|June 29, 2016
Overestimated value of FDG-PET based bone marrow evaluation in lymphomaHugo J A Adams, Thomas C Kwee
European Journal of Nuclear Medicine and Molecular Imaging|July 15, 2017
Unproven value of end-of-treatment FDG-PET in Hodgkin lymphomaHugo J A Adams, Thomas C Kwee
European Journal of Radiology|October 26, 2016
Proportion of false-positive lesions at interim and end-of-treatment FDG-PET in lymphoma as determined by histology: Systematic review and meta-analysisHugo J A Adams, Thomas C Kwee
British Journal of Haematology|December 28, 2016
Hodgkin lymphoma: is there really a need for interim and end-of-treatment FDG-PET evaluations?Hugo J A Adams, Thomas C Kwee
British Journal of Haematology|November 16, 2018
Interim FDG-PET does not predict outcome in advanced-stage Hodgkin lymphoma patients treated with BEACOPPHugo J A Adams, Thomas C Kwee
Pageof 26